Antios Therapeutics

What Antios Therapeutics does

Antios Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company founded in 2018 and headquartered in Atlanta, Georgia, focused on developing therapeutics to treat and functionally cure chronic hepatitis B virus (HBV) infection. Its lead candidate, ATI-2173, is described as the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in development; when combined with a standard nucleoside analogue such as tenofovir or entecavir in a once-daily oral regimen, the company positions the combination as capable of shutting down HBV polymerase activity and viral replication. The company is also developing fourth-generation capsid assembly modulators (CAMs) acquired from IRBM, INGM, and Ospedale San Raffaele, and has disclosed additional pipeline candidates ATI-1428 and ATI-1645.

The technology platform is rooted in small-molecule chemistry with a focus on differentiated mechanisms of action rather than computational or AI-driven discovery. Antios has secured composition-of-matter IP via a USPTO Notice of Allowance on phosphoramidates for HBV treatment and has reported Phase 1b and 2a suppression of HBV with ATI-2173, with Phase 2b combination studies and collaborations with Arbutus Biopharma and Assembly Biosciences underway. Leadership includes co-founders Abel De La Rosa (also CEO), Douglas Mayers (CMO), and Idean Marvasty, with Greg Mayes as president and CEO.

Because Antios is pre-commercial, the company does not yet generate product revenue. Its business model is expected to monetize through licensing, royalties, or partnership-based commercialization of ATI-2173 and related assets to large-pharma partners for global distribution to hepatologists, gastroenterologists, and infectious disease specialists serving a 290-million-patient global chronic HBV population. To date the company has financed operations through approximately $200 million of disclosed venture capital across a Series A, an unclassified 2020 round, and Series B and B-1 financings in 2021 led respectively by Soleus Capital and EPIQ Capital Group / GordonMD Global Investments.

Name

Antios Therapeutics

Legal name

Antios Therapeutics, Inc.

Website

https://antiostherapeutics.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Antios Therapeutics is a clinical-stage biopharmaceutical company developing ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), along with fourth-generation capsid assembly modulators, to achieve a functional cure for chronic hepatitis B virus in 290 million+ patients worldwide.

Ownership category

akta.pro rank

Headquarters

HQ city

Atlanta

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical Drug Development and Commercialization: Pre-revenue clinical-stage biopharmaceutical company. Future revenue expected from commercialization of ATI-2173 and other pipeline candidates for hepatitis B virus treatment through pharmaceutical sales, potentially via licensing agreements or direct commercialization partnerships.

Go-to-market motion1 record

Marketing channels4 records

Core offering

Antios Therapeutics is developing ATI-2173, the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in clinical development, intended to be combined with nucleoside analogues such as Tenofovir (TDF) or Entecavir (ETV) in a once-daily regimen to completely shut down HBV polymerase activity and viral replication, potentially achieving a functional cure. The company is also developing fourth-generation capsid assembly modulators (CAMs) and pipeline candidates ATI-1428 and ATI-1645 for chronic hepatitis B treatment.

Product overview

Antios Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of antiviral drug candidates targeting hepatitis B virus (HBV). The core product is ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), currently in Phase 2a clinical trials. The company is also developing fourth-generation capsid assembly modulators (CAMs) and additional pipeline candidates (ATI-1428, ATI-1645). The lead programs aim to achieve a functional cure for chronic HBV by combining the ASPIN with nucleoside analogues in a one-pill, once-daily regimen.

Differentiator

Problem solved

Functional benefit

Products and services

• ATI-2173 (ASPIN) Active Site Polymerase Inhibitor Nucleotide (ASPIN) drug candidate for chronic hepatitis B virus. Designed to be combined with nucleoside analogues such as Tenofovir or Entecavir in a once-daily regimen to completely shut down HBV polymerase activity and viral replication, with the potential to achieve a functional cure. Currently in Phase 2a combination studies.
• Fourth-Generation Capsid Assembly Modulators (CAMs) Fourth-generation capsid assembly modulators (CAMs) for the treatment of HBV with a differentiated mechanism of action that, unlike most CAMs, may provide more targeted, productive clearance of the virus by the immune system.
• ATI-1428 Pipeline compound for hepatitis B virus programs, presented at EASL International Liver Congress 2022.
• ATI-1645 Pipeline compound for hepatitis B virus programs, presented at EASL International Liver Congress 2022.

Quantifiable outcome

• Complete shutdown of HBV polymerase activity and viral replication
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core.

• Arbutus BiopharmacoreStrategic or Co-development Partner · 3 November 2021Collaboration with Arbutus Biopharma for combination clinical trials of ATI-2173 with Arbutus's HBV candidates. This strategic partnership combines complementary technologies for potential synergistic treatment approaches in chronic hepatitis B.
• Assembly BiosciencescoreStrategic or Co-development Partner · 3 November 2021Collaboration with Assembly Biosciences for combination clinical trials of ATI-2173 with Assembly's HBV candidates. This partnership explores combination therapies to advance functional cure approaches for chronic hepatitis B.
• IRBM (Istituto di Ricerca di Biologia Molecolare)coreStrategic or Co-development PartnerAgreement with IRBM, INGM (Istituto Nazionale di Genetica Molecolare), and OSR (Ospedale San Raffaele) to acquire fourth-generation HBV capsid assembly modulators (CAMs). This acquisition expands Antios's pipeline with differentiated CAM technology for HBV treatment.
• INGM (Istituto Nazionale di Genetica Molecolare)coreStrategic or Co-development PartnerAgreement with IRBM, INGM, and OSR to acquire fourth-generation HBV capsid assembly modulators (CAMs).
• OSR (Ospedale San Raffaele)coreStrategic or Co-development PartnerAgreement with IRBM, INGM, and OSR to acquire fourth-generation HBV capsid assembly modulators (CAMs).

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Arbutus Biopharma: Arbutus Biopharma is a clinical-stage biopharmaceutical company developing RNAi and oral capsid inhibitor approaches for chronic HBV functional cure. Directly comparable as an HBV-focused biotech with overlapping mechanisms, and is also one of Antios's named combination partners.
• Assembly Biosciences: Assembly Biosciences is a clinical-stage biotechnology company developing small molecule capsid inhibitor therapies for chronic HBV. Directly comparable as an HBV-specific therapeutic developer and a named Antios combination partner.
• Vir Biotechnology: Vir Biotechnology is a clinical-stage immunology company with a leading chronic HBV portfolio spanning siRNA and monoclonal antibody approaches. Comparable as a pure-play HBV biotech pursuing functional cure through nucleic acid and immunologic mechanisms.
• Brii Biosciences: Brii Biosciences is a clinical-stage biopharmaceutical company developing functional cure therapies for chronic HBV, including siRNA and monoclonal antibody assets. Directly comparable as an HBV-focused clinical-stage biotech with similar cure-oriented strategy.
• Arrowhead Pharmaceuticals: Arrowhead Pharmaceuticals is a clinical-stage biopharmaceutical company developing RNAi-based therapeutics, including candidates targeting HBV. Comparable as a nucleic acid platform developer pursuing functional cure in the same disease.
• Altimmune: Altimmune is a clinical-stage biopharmaceutical company that developed an immunotherapeutic vaccine candidate (HepTcell) for chronic HBV. Comparable as an HBV-focused biotech pursuing functional cure through an alternative mechanism.

Broad incumbents

• Gilead Sciences: Gilead Sciences markets Vemlidy (tenofovir alafenamide) and Viread (tenofovir disoproxil fumarate), the very nucleoside analogues Antios combines with, and remains the dominant commercial franchise in chronic HBV therapy. Comparable as the incumbent market leader whose generic NAs are central to Antios's regimen.
• GSK (GlaxoSmithKline): GSK has invested heavily in HBV cure research, including bepirovirsen, an antisense oligonucleotide for chronic HBV with positive Phase 3 data. Comparable as a large incumbent with significant HBV functional cure aspirations and complementary nucleic-acid mechanism.
• Roche: Roche has been a long-standing major player in HBV through Pegasys (peginterferon alfa-2a) and continues HBV research via Genentech. Comparable as a large incumbent with an established HBV franchise and ongoing cure research.

Emerging players

• Dicerna Pharmaceuticals (Novo Nordisk): Dicerna Pharmaceuticals (now part of Novo Nordisk) developed RNAi-based HBV therapeutics including RG6346, advancing the broader nucleic acid HBV cure landscape. Comparable as an RNAi-platform developer targeting functional cure in HBV with substantial big-pharma backing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks4 records

Key highlights7 records

Customer concentration

• Xtwitter.com/AntiosTx
• LinkedInlinkedin.com/company/antios

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Antios Therapeutics